Compare Abeona Therapeutics Inc (ABEO) vs Samsara Inc (IOT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Samsara Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Samsara Inc trades at $35.83 (market cap $21.18B). The key difference: Samsara Inc is far larger — about 56.7× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Samsara Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | IOT | |
|---|---|---|
Market Cap | $373.32M | $21.18B |
Sector | Health | Technology |
52-Week High | $7.23 | $45.22 |
52-Week Low | $4.17 | $24.25 |
Enterprise Value | $228.22M | $20.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Samsara (IOT) trades at $37.51, up 4.4% with strong bullish technical signals and consistent earnings beats. The company shows robust revenue growth projection from $1.25B (2025) to $1.7B (2026) and improving profitability, though current valuation metrics remain elevated with P/E of 375. Recent product launches including tracking labels and AI capabilities demonstrate innovation momentum in the connected operations space.
While analyst consensus remains strongly bullish with 78% buy ratings and $44.40 price target, investors face valuation concerns and execution risks as the company transitions toward profitability. The stock's technical overbought condition near resistance levels suggests potential near-term consolidation before further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Samsara Inc
Samsara provides a connected operations cloud that uses IoT data to help businesses improve efficiency and safety. Its platform offers real-time visibility for fleet management, equipment monitoring, and industrial sites.
Read more on IOT →
